ProCE Banner Activity

Improved Survival and Response With Lenvatinib ± Everolimus vs Everolimus Alone in Metastatic RCC

Slideset Download
Conference Coverage
Phase II results indicate promising efficacy of second-line treatment with lenvatinib alone or in combination with everolimus in mRCC.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation